ERBB2 and biliary tract neoplasm: Recently, studies on targeted therapy have pointed out that there are many potential mutations in biliary tract cancer such as mutations of P53 [25], HER2 [26] and other molecular vulnerabilities, which can be used as therapeutic targets.